233 related articles for article (PubMed ID: 22753904)
1. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Van Cutsem E; Tejpar S; Vanbeckevoort D; Peeters M; Humblet Y; Gelderblom H; Vermorken JB; Viret F; Glimelius B; Gallerani E; Hendlisz A; Cats A; Moehler M; Sagaert X; Vlassak S; Schlichting M; Ciardiello F
J Clin Oncol; 2012 Aug; 30(23):2861-8. PubMed ID: 22753904
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.
Fora AA; McMahon JA; Wilding G; Groman A; Ma WW; Romano KS; Fakih MG
Oncology; 2013; 84(4):210-3. PubMed ID: 23328486
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Tabernero J; Ciardiello F; Rivera F; Rodriguez-Braun E; Ramos FJ; Martinelli E; Vega-Villegas ME; Roselló S; Liebscher S; Kisker O; Macarulla T; Baselga J; Cervantes A
Ann Oncol; 2010 Jul; 21(7):1537-1545. PubMed ID: 19940007
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.
Mrabti H; De la Fouchardiere C; Desseigne F; Dussart S; Negrier S; Errihani H
J Cancer Res Ther; 2009; 5(4):272-6. PubMed ID: 20160361
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Tabernero J; Cervantes A; Rivera F; Martinelli E; Rojo F; von Heydebreck A; Macarulla T; Rodriguez-Braun E; Eugenia Vega-Villegas M; Senger S; Ramos FJ; Roselló S; Celik I; Stroh C; Baselga J; Ciardiello F
J Clin Oncol; 2010 Mar; 28(7):1181-9. PubMed ID: 20100964
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
Wilke H; Glynne-Jones R; Thaler J; Adenis A; Preusser P; Aguilar EA; Aapro MS; Esser R; Loos AH; Siena S
J Clin Oncol; 2008 Nov; 26(33):5335-43. PubMed ID: 18854570
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
13. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Chan E; Kwak EL; Hwang J; Heiskala M; de La Bourdonnaye G; Mita M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):701-9. PubMed ID: 25627002
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Roca JM; Alonso V; Pericay C; Escudero P; Salud A; Losa F; López LJ; Guasch I; Méndez M; Quintero-Aldana G; Grande C; Vicente P; Arrivi A; Martin C; Moreno I; García P; Antón I; Constenla M; Yubero A; Cirera L;
Chemotherapy; 2010; 56(2):142-6. PubMed ID: 20407241
[TBL] [Abstract][Full Text] [Related]
16. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
[TBL] [Abstract][Full Text] [Related]
20. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
